ArticlePurinergic signalling2007
P1 receptors and cytokine secretion.
Article in Purinergic signalling, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 65 citations in OpenAlex.
- Renal Ischemia-Reperfusion and Uremic Toxins Modulate the Aortic Adenosinergic Axis in Acute Kidney Injury.International journal of molecular sciences · 2026Article
- Extracellular Vesicles and Purinergic Signaling in Alzheimer's Disease-Joining Forces for Novel Therapeutic Approach.Brain sciences · 2025Review
- Pharmacological interaction and immune response of purinergic receptors in therapeutic modulation.Purinergic signalling · 2024Review
- Adenosine in Interventional Cardiology: Physiopathologic and Pharmacologic Effects in Coronary Artery Disease.International journal of molecular sciences · 2024Review
- Effect of adenosine treatment on ionizing radiation toxicity in zebrafish early life stages.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Roles of Adenosine Receptor (subtypes AMolecular neurobiology · 2023Article
- Adenosine and the Cardiovascular System.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2019Review
- Microglia in Alzheimer Disease: Well-Known Targets and New Opportunities.Frontiers in aging neuroscience · 2019Review
- Role of purinergic receptors in the Alzheimer's disease.Purinergic signalling · 2018Review
- Adenosine A2A receptor agonist ameliorates EAE and correlates with Th1 cytokine-induced blood brain barrier dysfunction via suppression of MLCK signaling pathway.Immunity, inflammation and disease · 2018Article
- Enzymes that hydrolyze adenine nucleotides in a model of hypercholesterolemia induced by Triton WR-1339: protective effects of β-caryophyllene.Molecular and cellular biochemistry · 2017Article
- Adenosine A2B Receptors - Mediated Induction of Interleukin-6 in Skeletal Muscle Cells.Turkish journal of pharmaceutical sciences · 2017Article
- Purinergic receptors as potential therapeutic targets in Alzheimer's disease.Neuropharmacology · 2016Review
- Neuroinflammation after neonatal hypoxia-ischemia is associated with alterations in the purinergic system: adenosine deaminase 1 isoenzyme is the most predominant after insult.Molecular and cellular biochemistry · 2015Article
- Purine-metabolizing ectoenzymes control IL-8 production in human colon HT-29 cells.Mediators of inflammation · 2014Article
- Glial adenosine kinase--a neuropathological marker of the epileptic brain.Neurochemistry international · 2013Review
- Neurotransmitter signaling in the pathophysiology of microglia.Frontiers in cellular neuroscience · 2013Article
- Adenosine deaminase activity in serum and lymphocytes of rats infected with Sporothrix schenckii.Mycopathologia · 2012Article
- Differential macrophage activation alters the expression profile of NTPDase and ecto-5'-nucleotidase.PloS one · 2012Article
- Adenosine and immune imbalance in visceral leishmaniasis: the possible role of ectonucleotidases.Journal of tropical medicine · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evidence has accumulated in the last three decades to suggest tissue protection and regeneration by adenosine in multiple different cell types. Adenosine produced in hypoxic or inflamed environments reduces tissue injury and promotes repair by receptor-mediated mechanisms. Among other actions, regulation of cytokine production and secretion by immune cells, astrocytes and microglia (the brain immunocytes) has emerged as a main mechanism at the basis of adenosine effects in diseases characterized by a marked inflammatory component. Many recent studies have highlighted that signalling through A(1) and A(2A) adenosine receptors can powerfully prevent the release of pro-inflammatory cytokines, thus inhibiting inflammation and reperfusion injury. However, the activation of adenosine receptors is not invariably protective of tissues, as signalling through the A(2B) adenosine receptor has been linked to pro-inflammatory actions which are, at least in part, mediated by increased release of pro-inflammatory cytokines from epithelial cells, astrocytes and fibroblasts. Here, we discuss the multiple actions of P1 receptors on cytokine secretion, by analyzing, in particular, the role of the various adenosine receptor subtypes, the complex reciprocal interplay between the adenosine and the cytokine systems, their pathophysiological significance and the potential of adenosine receptor ligands as new anti-inflammatory agents.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.